AnhydroicaritinCAS# 38226-86-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 38226-86-7 | SDF | Download SDF |
PubChem ID | 14583584 | Appearance | Yellow powder |
Formula | C21H20O6 | M.Wt | 368.38 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3,5-dihydroxy-2-(4-methoxyphenyl)-8,8-dimethyl-9,10-dihydropyrano[2,3-h]chromen-4-one | ||
SMILES | CC1(CCC2=C3C(=C(C=C2O1)O)C(=O)C(=C(O3)C4=CC=C(C=C4)OC)O)C | ||
Standard InChIKey | PPCHTBBOSVKORE-UHFFFAOYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Anhydroicaritin exhibits immunosuppressive effects and has strong activity in scavenging DPPH radical. Anhydroicaritin can improve diet-induced obesity and hyperlipidemia and alleviate insulin resistance by suppressing SREBPs activation, it can serve as a leading compound for pharmacological control of metabolic diseases. Anhydroicaritin has the potential of stimulating the formation of mineralization nodules and further speeding up the formation of bone, it possesses significant protective effects on the zymosan-induced peritonitis mice, which may be associated with the regulation ofCa2+, influx in macrophages and iNOS expression. |
Targets | AMPK | mTOR | NO | IL Receptor | TNF-α | NOS | Calcium Channel |
In vitro | Effects of anhydroicaritin on the immunologic function of mouse macrophages.[Pubmed: 22482407]Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Apr;28(4):374-6.To investigate the effects of Anhydroicaritin (AHI) on the immunologic function of mouse macrophages stimulated by lipopolysaccharide (LPS) in vitro and its related immunosuppressive mechanism.
Study on antioxidant activities of icariin and anhydroicaritin[Reference: WebLink]Journal of Shaanxi Normal University, 2012, 40(3):73-6.The antioxidant activities of the icariin and Anhydroicaritin were investigated by using 1,1-diphenyl-2-picryl-hydrazyl radical scavenging assay(DPPH·),superoxide radical scavenging assay(O2-·),hydroxyl radical scavenging assay(OH·),total antioxidant activity,and lipid peroxidation assay.
|
In vivo | Protective effect of anhydroicaritin against peritonitis in mice.[Pubmed: 24103264 ]Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Oct;29(10):1036-9.To investigate the effect of Anhydroicaritin (AHI) against zymosan-induced peritonitis in mice.
|
Kinase Assay | Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation.[Pubmed: 27816546 ]Biochem Pharmacol. 2016 Dec 15;122:42-61.SREBPs play important roles in the regulation of lipid metabolism, and are closely related to the occurrence and development of many metabolic diseases.
Small molecular inhibitors of SERBPs are important tools in developing efficient treatment of metabolic diseases. However, there are no listing drug targeting SREBPs. Therefore, there is an urgent need to develop highly specific small molecules that inhibit SREBPs.
|
Cell Research | Effects of anhydroicaritin and 2[Pubmed: 23285807]Nat Prod Commun. 2012 Nov;7(11):1461-4.Epimedium brevicornu Maxim., one of the most frequently used traditional Chinese medicines for thousands of years, is prescribed as having "bone strengthening" function and the ability to cure bone diseases.
|
Anhydroicaritin Dilution Calculator
Anhydroicaritin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7146 mL | 13.5729 mL | 27.1459 mL | 54.2918 mL | 67.8647 mL |
5 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL | 10.8584 mL | 13.5729 mL |
10 mM | 0.2715 mL | 1.3573 mL | 2.7146 mL | 5.4292 mL | 6.7865 mL |
50 mM | 0.0543 mL | 0.2715 mL | 0.5429 mL | 1.0858 mL | 1.3573 mL |
100 mM | 0.0271 mL | 0.1357 mL | 0.2715 mL | 0.5429 mL | 0.6786 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Filixic acid ABA
Catalog No.:BCN6330
CAS No.:38226-84-5
- Pyroxamide
Catalog No.:BCC2424
CAS No.:382180-17-8
- Coumarin VI
Catalog No.:BCN7833
CAS No.:38215-36-0
- Bacopaside II
Catalog No.:BCC8125
CAS No.:382146-66-9
- Adrenosterone
Catalog No.:BCC4061
CAS No.:382-45-6
- Sulindac
Catalog No.:BCC4861
CAS No.:38194-50-2
- 7,8-Dihydroxyflavone
Catalog No.:BCC6072
CAS No.:38183-03-8
- Bephenium Hydroxynaphthoate
Catalog No.:BCC3735
CAS No.:3818-50-6
- 28-Hydroxy-3-oxoolean-12-en-29-oic acid
Catalog No.:BCN1449
CAS No.:381691-22-1
- Brevianamide F
Catalog No.:BCN6452
CAS No.:38136-70-8
- Streptomycin sulfate
Catalog No.:BCC4851
CAS No.:3810-74-0
- Perampanel
Catalog No.:BCC1847
CAS No.:380917-97-5
- Enhydrin chlorohydrin
Catalog No.:BCN4639
CAS No.:38230-99-8
- beta-Amyrenonol
Catalog No.:BCN5436
CAS No.:38242-02-3
- 20(R)-Ginsenoside Rg3
Catalog No.:BCN5018
CAS No.:38243-03-7
- Malonomicin
Catalog No.:BCN1844
CAS No.:38249-71-7
- Glucose-conjugated MGMT inhibitor
Catalog No.:BCC1597
CAS No.:382607-78-5
- Burchellin
Catalog No.:BCN6676
CAS No.:38276-59-4
- Naringenin trimethyl ether
Catalog No.:BCN5437
CAS No.:38302-15-7
- Minoxidil
Catalog No.:BCC4297
CAS No.:38304-91-5
- YE 120
Catalog No.:BCC6188
CAS No.:383124-82-1
- 3-O-beta-D-Glucopyranosylplatycodigenin
Catalog No.:BCN7832
CAS No.:38337-25-6
- Homovanillic Acid Sulfate
Catalog No.:BCN2226
CAS No.:38339-06-9
- UC 112
Catalog No.:BCC8042
CAS No.:383392-66-3
[Effects of anhydroicaritin on the immunologic function of mouse macrophages].[Pubmed:22482407]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Apr;28(4):374-6.
AIM: To investigate the effects of Anhydroicaritin (AHI) on the immunologic function of mouse macrophages stimulated by lipopolysaccharide (LPS) in vitro and its related immunosuppressive mechanism. METHODS: Mouse bone marrow-derived macrophages were isolated. Then, the drug toxicology of different concentrations of AHI on macrophages was measured by CCK-8 assay. The amount of NO produced in macrophages was detected by Griess kit. The phagocytosis of macrophages to E.coli BioParticles was assayed by flow cytometry (FCM). The expression of CD69, which was the marker of early activation of macrophages, was measured by FCM combined with two-color immunofluorescent staining of cell surface antigen. Cytometric bead array (CBA) kit was used to detect the production of cytokines of macrophages stimulated by LPS. RESULTS: AHI (2.5, 5, 10 mumol/L) significantly reduced the production of NO in macrophages stimulated by LPS, and inhibited the phagocytosis of activated macrophages. The results of FCM analysis showed that AHI decreased proportions of CD69 on LPS-stimulated macrophages. Furthermore, AHI downregulated the secretion of cytokines of LPS-induced macrophages. CONCLUSION: AHI, which exhibits immunosuppressive effect on the mouse macrophages stimulated by LPS, is promising to be developed as an immunosuppressive reagent.
[Protective effect of anhydroicaritin against peritonitis in mice].[Pubmed:24103264]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Oct;29(10):1036-9.
OBJECTIVE: To investigate the effect of Anhydroicaritin (AHI) against zymosan-induced peritonitis in mice. METHODS: Peritonitis was induced in mice by intraperitoneal injection of zymosan. All mice were monitored for systemic toxicity and mortality for 13 d after zymosan or saline administration. In another set of experiments, the peritoneal exudates were collected. The leukocyte numbers and the production of inflammatory cytokines (IL-6, IL-10, TNF-alpha, MCP-1) were determined by flow cytometry. The release of nitric oxide (NO) was measured by a Griess reagent system. The Ca(2+); influx in bone marrow-derived macrophages was recorded by laser scanning confocal microscopy with Fluo4-AM loading. The expression of iNOS was determined by Western blotting. RESULTS: AHI (4 mg/kg) prolonged survival of peritonitis mice, inhibited massive leukocyte transmigration into the peritoneal cavity, and decreased the overproduction of NO, IL-10, TNF-alpha, MCP-1 and IL-6. In LPS-stimulated mouse macrophages, AHI (5 mumol/L) pretreatment significantly inhibited the elevation of intracellular Ca(2+);, and markedly decreased iNOS protein expression. CONCLUSION: AHI possesses significant protective effects on the zymosan-induced peritonitis mice, which might be associated with the regulation of Ca(2+); influx in macrophages and iNOS expression.
Effects of anhydroicaritin and 2"-hydroxy-3"-en-anhydroicaritin on the proliferation and differentiation of MC3T3-E1 osteoblasts.[Pubmed:23285807]
Nat Prod Commun. 2012 Nov;7(11):1461-4.
Epimedium brevicornu Maxim., one of the most frequently used traditional Chinese medicines for thousands of years, is prescribed as having "bone strengthening" function and the ability to cure bone diseases. The present study evaluated the osteogenic effects of Anhydroicaritin (1) and 2"-hydroxy-3"-enAnhydroicaritin (2) isolated from E. brevicornu by activity-guided assay. Treatment with 1 and 2 improved the proliferation of murine osteoblastic MC3T3-E1 cells at doses of 10(-7)-10(-5) mol/L and 10(-7)-10(-6) mol/L, respectively, in the 72-hour culture period. Enzyme linked immunosorbent assay and histochemical staining demonstrated that both of these two prenyl-flavonoids significantly promoted the differentiation of MC3T3-E1 cells by enhancing the level of ALP activity in the cells. Alizarin Red staining and mineralized nodule quantification showed that 1 and 2 had the potential of stimulating the formation of mineralization nodules and further speeding up the formation of bone, indicating that both compounds might be potential candidates for bone regenerative medicine.
Anhydroicaritin improves diet-induced obesity and hyperlipidemia and alleviates insulin resistance by suppressing SREBPs activation.[Pubmed:27816546]
Biochem Pharmacol. 2016 Dec 15;122:42-61.
SREBPs play important roles in the regulation of lipid metabolism, and are closely related to the occurrence and development of many metabolic diseases. Small molecular inhibitors of SERBPs are important tools in developing efficient treatment of metabolic diseases. However, there are no listing drug targeting SREBPs. Therefore, there is an urgent need to develop highly specific small molecules that inhibit SREBPs. In this study, using a hepatocyte-based high-throughput screening, we identified Anhydroicaritin (AHI) as a novel inhibitor of SREBPs. HepG2, HL-7702, and human primary hepatocytes were used to verify the effects of AHI. We explored the mechanism by which AHI blocks the binding of SCAP/SREBPs complex with Sec23alpha/24D via regulating LKB1/AMPK/mTOR pathway. AHI reduced liver cell lipid level by preventing de novo lipogenesis. In diet induced obese mice, AHI ameliorated obesity, insulin resistance, fatty accumulation in liver and hyperlipemia. In conclusion, AHI improves diet-induced obesity and alleviates insulin resistance by suppressing SREBPs maturation which is dependent on LKB1/AMPK/mTOR pathway. Thus, AHI can serve as a leading compound for pharmacological control of metabolic diseases.